DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Sweden
  • /
  • Healthcare
Author Program NEWCreate Narrative
EKTA B logo

Elekta AB (publ) Stock Price

OM:EKTA B Community·SEK 19.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 22 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

EKTA B Share Price Performance

SEK 50.05
3.91 (8.47%)
​
SEK 60.50
Fair Value
SEK 50.05
3.91 (8.47%)
17.3% undervalued intrinsic discount
SEK 60.50
Fair Value
Price SEK 50.05
AnalystConsensusTarget SEK 60.50
AnalystLowTarget SEK 39.00
AnalystHighTarget SEK 92.79
Mon, 15 Jun 26
Fair ValueSEK 60.50
Share Pricen/a

EKTA B Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value SEK 60.5 17.3% undervalued intrinsic discount

European Launches And Chinese Recovery Will Expand Precision Radiotherapy Adoption

0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value SEK 39 28.3% overvalued intrinsic discount

Rising Trade Barriers And Competition Will Squeeze MedTech Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value SEK 92.79 46.1% undervalued intrinsic discount

Adaptive Radiotherapy And AI Convergence Will Expand Emerging Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
EKTA B logo
Elekta
17.3% undervalued intrinsic discount

European Launches And Chinese Recovery Will Expand Precision Radiotherapy Adoption

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 15 Jun
Read Narrative
EKTA B logo
Elekta
46.1% undervalued intrinsic discount

Adaptive Radiotherapy And AI Convergence Will Expand Emerging Markets

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 1 Jun
Read Narrative
EKTA B logo
Elekta
28.3% overvalued intrinsic discount

Rising Trade Barriers And Competition Will Squeeze MedTech Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 1 May
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
EKTA B logo

EKTA B: Future Returns Will Rely On Margin Delivery Versus Cautious Ratings

Fair Value: SEK 60.5 17.3% undervalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
EKTA B logo

EKTA B: Transformation Progress And Cost Savings Will Support Medium Term Upside

Fair Value: SEK 92.79 46.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
EKTA B logo

EKTA B: Heightened Execution Risks Will Challenge Higher P E Assumptions

Fair Value: SEK 39 28.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with high growth potential and pays a dividend.

2 Risks
3 Rewards
View Full Analysis

Elekta AB (publ) Key Details

SEK 16.6b

Revenue

SEK 10.0b

Cost of Revenue

SEK 6.6b

Gross Profit

SEK 6.9b

Other Expenses

-SEK 362.0m

Earnings

Last Reported Earnings
Jul 31, 2026
Next Reporting Earnings
Nov 25, 2026
-0.91
39.60%
-2.18%
76.7%
View Full Analysis

About EKTA B

Founded
1972
Employees
3996
CEO
Jakob Just-Bomholt
WebsiteView website
www.elekta.com

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear machines and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo, a CT-Linac solution; Elekta Versa HD, a brain metastases solution; Elekta Harmony; and Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs, as well as quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit, a gamma knife system; and Elekta Care, a personalized services for radiotherapy suites. In addition, the company offers brachytherapy products, including Elekta Studio, an image-guided brachytherapy solution; ImagingRing for dynamic imaging; Oncentra Brachy, a smart tool that facilitates repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Elekta Geneva, an applicator for cervical cancer patients; and Elekta Xoft Axxent electronic brachytherapy systems. Further, it provides Leksell Vantage Stereotactic System, a neurosurgery product; Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. Additionally, the company offers Elekta Care 360, which provides a range of clinical and professional services; Elekta Care Learning; Elekta Care Community, a self-help center; and Elekta Partner Community, an online self-service portal. Elekta AB (publ) was incorporated in 1972 and is headquartered in Stockholm, Sweden.

Recent EKTA B News & Updates

Recent updates

No updates

Elekta AB (publ) Competitors

GETI B logo

Getinge

Symbol: OM:GETI B
Market cap: SEK 64.9b
SECT B logo

Sectra

Symbol: OM:SECT B
Market cap: SEK 54.9b
MCOV B logo

Medicover

Symbol: OM:MCOV B
Market cap: SEK 36.2b
ASKER logo

Asker Healthcare Group

Symbol: OM:ASKER
Market cap: SEK 27.1b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide